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A b s t r a c t
Background: Rotational atherectomy (RA) is indicated for fibrocalcified lesions when traditional percutaneous coronary 
intervention (PCI) could not be successfully performed. In some of the high-risk patients the RA procedure is the last resort 
for successful revascularisation. Such patients are, among others, those in whom coronary artery bypass grafting (CABG) is 
not feasible.
Aim: The aim of the study was to assess in-hospital and one-year outcomes of PCI with RA in high-risk patients without other 
revascularisation options (RA-only group), in comparison to lower-risk patients undergoing RA.
Methods: We evaluated data of 207 consecutive patients who underwent PCI with RA. Primary endpoints were one-year 
all-cause mortality and one-year major adverse cardiac events (MACEs). Secondary endpoints were in-hospital outcomes.
Results: During the study 35% of patients fulfilled the inclusion criteria to the high-risk group. Those patients had significantly 
lower left ventricular ejection fraction, more often prior CABG, higher admission glucose level, and higher EuroSCORE II and 
Syntax Score. Procedural success was similar in both groups (85% in RA-only group vs. 91% in remaining patients, p = 0.18). 
In-hospital outcomes were similar, except more frequent no/slow-flow phenomenon in the RA-only group. The MACE and 
mortality rates in one-year follow-up were not statistically different in both groups (19% vs. 18%, p = 0.82 and 11% vs. 9%, 
p = 0.64, respectively).
Conclusions: Despite the high-risk characteristics of the study subgroup, no significant differences between in-hospital and 
one-year outcomes were found in comparison to lower-risk RA patients. Complex PCI with RA in patients without other 
revascularisation options should be taken into consideration.
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INTRODUCTION
Rotational atherectomy (RA) is known as a bailout technique, 
and according to European and American recommenda-
tions it is indicated for calcified or massive fibrotic plaque 
modifications, when traditional balloon dilatations cannot be 
performed and optimal stent implantation is unavailable [1, 2]. 
Some of the patients with severe coronary artery disease 
constitute a high-risk population, and the RA procedure is 
their last resort for successful revascularisation. Such patients 
are, among others, those in whom coronary artery bypass 
grafting (CABG) is not feasible. The most common reasons 
for disqualification from CABG are major comorbidities 
increasing surgery risk, and challenging anatomy, including 
poor periphery of coronary arteries or prior CABG with patent 
grafts [3–5]. Conservative treatment alone in cases of extensive 
symptomatic ischaemia also seems to be insufficient [6–8]. 
Hence, there is a group of patients in whom RA remains the 
only revascularisation option. Other potential methods for 
invasive treatment of heavily calcified lesions include orbital 
atherectomy and laser atherectomy, but they remain under 
investigation and are not available in every country.
Of note, in general the prognosis of patients with multi-
vessel coronary disease who are ineligible or disputable for 
CABG, and who underwent percutaneous coronary interven-
tion (PCI), is poor, which is associated with a complex clinical 
and coronary anatomy profile [9–12]. For this reason, an 
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initiative called Complex Higher-Risk and Indicated Patients 
(CHIP) Fellowship was created to advocate the necessity of 
special interventional training, including RA, so that high-risk 
PCI procedures can be performed with success.
Therefore, the purpose of this study was to assess the risk 
profile, safety, efficacy, and one-year outcomes of PCI with 
associated RA in patients with a high-risk profile and without 
other revascularisation options. A control group consisted of 




This single–, high-volume–centre observational study included 
all consecutive patients with symptomatic coronary artery dis-
ease who underwent PCI with RA in our institution from April 
2008 to October 2015. During this time period an average of 
1750 PCIs per year were performed, and were accompanied 
by RA in an average of ~2% of cases. There were no exclusion 
criteria. Baseline demographics, clinical characteristics, and 
detailed procedural data were collected, including indications 
for the procedure, urgency level, and lesion characteristics 
with basic quantitative coronary angiography parameters.
Preprocedural disqualification from CABG, if necessary, 
was undertaken by the local Heart Team, including at least one 
experienced cardiac surgeon, an experienced interventional 
cardiologist, and a general cardiologist who was in charge of 
the patient. Information on all postprocedural complications 
as well as in- and out-of-hospital major adverse cardiovascu-
lar events (MACEs) was collected. All patients gave informed 
consent to participate in the study. Follow-up data regarding 
all-cause mortality, recurrent hospitalisations, and MACEs was 
obtained from the Polish National Health Fund database, so no 
patient was lost to follow-up. The study protocol was accepted 
by the local Bioethics Committee and was in accordance with 
the Declaration of Helsinki.
Study definitions
A subgroup of high-risk patients (RA-only group) was subse-
quently distinguished from all study participants. It included 
patients in whom an attempt for traditional PCI was unsuc-
cessful and who were concurrently disqualified from CABG by 
the Heart Team. The control group consisted of the remaining 
all-comer patients who underwent RA in our centre during 
the study period.
The RA procedure was performed mainly due to the 
presence of undilatable lesions (defined as lesions that could 
not be adequately dilated by a balloon during inflation) or 
uncrossable lesions (defined as lesions that could be crossed 
by a wire but could not be crossed by even the smallest bal-
loons). The third primary reason to perform RA was its direct 
use in cases of severe massive calcifications of coronary vessels 
visible in angiography or failure of previous PCI for unclear 
reasons (in patients transferred from other catheterisation 
laboratories). The clinical risk was accessed according to the 
logistic EuroSCORE II and baseline Syntax Score (SS) along 
with residual SS and SS II. SS was calculated by two inter-
ventional cardiologists, and in cases of inconsistency the third 
calculation was done by a supervising cardiologist. The Syntax 
Revascularisation Index (SRI) was calculated with the follow-
ing formula: SRI = (1 – [residual SS/baseline SS]) × 100 [13].
Endpoint definitions
Primary endpoints were one-year all-cause mortality and 
one-year MACE defined as the composite endpoint of 
all-cause mortality, follow-up myocardial infarction (MI), and 
stroke. Secondary endpoints were procedural success and 
in-hospital outcome.
Baseline and follow-up MI was defined according to the 
universal definition of MI [14]. Procedural success was defined 
as angiographic success (residual stenosis of < 30% after stent 
implantation with thrombolysis in myocardial infarction flow 
grade III) without periprocedural complications. Contrast-in-
duced nephropathy (CIN) was defined as a relative increase 
in serum creatinine concentration > 25% or as an absolute 
increase in serum creatinine concentration > 0.5 mg/dL from 
baseline within 72 h of PCI. Relevant access site bleeding was 
defined as at least type 3a according to the Bleeding Academic 
Research Consortium [15].
Procedure
Rotational atherectomy procedure was performed using stand-
ard Boston Scientific Rotablator system (Boston Scientific, 
Marlborough, MA, USA). All procedures were performed by 
trained rotablator operators with a long experience in PCI. 
Radial or femoral route was used according to operator’s 
discretion. Burr speed ranged from 140,000 to 180,000 rpm 
with a run duration of ~20 to 30 s. In all procedures an in-
tracoronary continuous infusion of heparin, verapamil, and 
isosorbide dinitrate via a burr sheath was used. Heparin was 
given to maintain an activated clotting time > 250 s. All pa-
tients were pretreated with acetylsalicylic acid and clopidogrel, 
except three patients treated with ticagrelor and one treated 
with prasugrel. In-hospital treatment before and after RA was 
conducted according to current standards, including adequate 
pharmacotherapy in patients with comorbidities such as heart 
failure, atrial fibrillation, and diabetes mellitus, which was 
left to the discretion of physicians in charge of the patients.
Statistical analysis
Continuous variables with normal distribution are presented 
as mean ± standard deviation, continuous variables with 
skewed distribution as median with interquartile range, 
and categorical variables as numbers and percentages. For 
continuous variables, intergroup differences were compared 
using Student t test or the Mann-Whitney U test, depending 
on the type of distribution. The c2 test was used to compare 
categorical variables. Univariate and multivariate Cox propor-
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tional hazard models were used to determine the predicting 
factors of all-cause death and composite endpoint (MACE). 
The multivariate model included all variables with p < 0.05 in 
the univariate model. Survival and event-free survival curves 
were created using the Kaplan-Meier method. Differences in 
survival and event-free survival rates were compared using 
the log-rank test. A p-value < 0.05 was considered statisti-
cally significant. All statistical analyses were performed using 
Statistica 10.0 (StatSoft, Tulsa, OK, USA) software.
RESULTS
Patient characteristics
During the study period 73 (35%) out of 207 patients ful-
filled the inclusion criteria to the high-risk (RA-only) group. 
The control group consisted of the remaining 134 (65%) 
all-comer patients, who underwent PCI with accompanying 
RA in the centre during this time. In the RA-only group 83% 
of patients were considered too high-risk for CABG, based 
on major comorbidities including extracardiac arteriopathy, 
chronic lung diseases, previous cardiac surgery, poor mobility, 
or mental status. The remaining 17% of patients had small 
or poor-quality peripheral vessels. The RA procedure was 
mainly performed due to the presence of uncrossable lesions 
(23%), undilatable lesions (52%), and severely calcified lesions 
or unsuccessful prior PCI attempt for unclear reasons (25%).
Baseline demographics, comorbidities, and laboratory 
results of the whole group and both subgroups are presented 
in Table 1. RA-only patients had worse left ventricular func-
tion with more frequent low left ventricular ejection fraction 
(LVEF) < 35% (25% vs. 13%, p = 0.03), more often prior 
CABG (40% vs. 1%, p < 0.001), and higher glucose level on 
admission (118 mg/dL vs. 106 mg/dL, p = 0.02). Both logis-
tic EuroSCORE II (4.1 vs. 1.8, p < 0.001) and SS (23 vs. 16, 
p < 0.001) along with residual SS (12 vs. 6, p < 0.001) were 
significantly higher in the RA-only group, whereas SRI was 
lower (47 vs. 71, p < 0.001) in this subset of patients. The 
prevalence of other cardiovascular risk factors, multiple co-
morbidities, and medications at discharge was similar in both 
groups, apart from diuretics, which were used more often in 
the RA-only group.
Procedure characteristics
Procedure characteristics are summarised in Table 2. RA pro-
cedure was performed in an acute coronary syndrome setting 
more often in the RA-only group (31% vs. 14%, p < 0.01). 
There was a trend towards less frequent transradial approach 
(52% vs. 65%, p = 0.07) and more frequent mechanical 
circulatory support use (4% vs. 1%, p = 0.09) in RA-only pa-
tients, as well as longer fluoroscopy time (23 min vs. 20 min, 
p = 0.08). There were no differences in other procedural 
and lesion characteristics and no difference in procedural 
success between RA-only group and the remaining patients 
(85% vs. 91%, p = 0.18).
In-hospital and one-year outcomes
In-hospital and one-year outcomes are presented in Table 3 
and Figure 1. The no/slow-flow phenomenon was observed 
more frequently in RA-only patients (4% vs. 0%, p = 0.02), 
and there was a trend towards more frequent access site 
bleedings in this group (11% vs. 4%, p = 0.08). There were no 
other differences in complication rates. In-hospital outcomes, 
including death, periprocedural MI, stroke, and CIN, were 
similar in both study groups.
At one-year follow-up the differences in mortality and 
MACE rates, including death, MI, and stroke, were not signifi-
cant between the RA-only group and the remaining patients 
(11% vs. 9%, p = 0.64 and 19% vs. 18%, p = 0.82, respec-
tively). Kaplan-Meier curves were plotted to assess survival data 
(Fig. 2) and MACE-free survival data (Fig. 3) for the RA-only 
group and the remaining patients. Values of the log-rank test 
comparison demonstrated non-significant differences in survival 
rates and MACE-free survival rates in both study groups.
Predictors of adverse events in one-year follow-up
In the whole study population, multivariate analysis revealed 
heart failure with LVEF ≤ 35% (hazard ratio [HR] 4.85, 95% 
confidence interval [CI] 1.72–13.67, p < 0.01) and uncross-
able lesion, as compared to undilatable lesion (HR 4.33, 
95% CI 1.71–10.94, p < 0.01), as independent predictors 
of one-year mortality and one-year MACE (HR 2.85, 95% 
CI 1.38–5.86, p < 0.01 and HR 2.15, 95% CI 1.15–4.03, 
p = 0.02, respectively; Table 4). It should be emphasised 
that among study participants the qualification to the RA-only 
subgroup was not associated with significantly higher one-year 
mortality (HR 2.45, 95% CI 0.89–6.75, p = 0.08) or with 
higher MACE rate (HR 1.46, 95% CI 0.79–2.69, p = 0.23).
DISCUSSION
In the study we analysed the high-risk population of patients 
who underwent an RA procedure as the last resort for success-
ful coronary revascularisation, in comparison to the remain-
ing all-comer population undergoing RA. The main findings 
of the study are: 1) clinical and coronary high-risk patients 
without other revascularisation options apart from RA consti-
tute a considerable population; 2) in-hospital and one-year 
outcomes are similar in high- and lower-risk patients after RA; 
3) complex PCI with accompanying RA in patients without 
other revascularisation options has acceptable prognosis and 
should be taken into consideration.
One-third of the patients who underwent PCI with ac-
companying RA in our centre had a high-risk clinical and 
anatomical profile and had no revascularisation alternative. 
In this subgroup traditional PCI was unsuccessful because of 
the presence of tough fibrocalcified lesions that could not 
be crossed or dilated by conventional angioplasty balloons, 
which is considered the main indication to perform the more 
complex procedure of rotablation [1, 2]. Additionally, these 
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Table 1. Baseline clinical and laboratory characteristics
Parameters All patients (n = 207) RA-only (n = 73) Remaining (n = 134) p
Age [years] 71 ± 9 72 ± 9 70 ± 9 0.15
Male sex 137 (66) 51 (70) 86 (64) 0.41
Hypertension 170 (82) 59 (81) 111 (83) 0.72
Diabetes mellitus 88 (43) 36 (49) 52 (39) 0.14
Prior stroke/TIA 26 (13) 13 (18) 13 (10) 0.09
Hyperlipidaemia 96 (46) 31 (42) 65 (49) 0.40
Thyroid disease 28 (14) 8 (11) 20 (15) 0.43
Cancer 25 (12) 8 (11) 17 (13) 0.72
Asthma/COPD 14 (7) 7 (10) 7 (5) 0.23
Current smoker 15 (7) 2 (3) 13 (10) 0.06
Atrial fibrillation 44 (21) 14 (19) 30 (22) 0.59
Peripheral artery disease 64 (31) 28 (38) 36 (27) 0.09
Severe valve disease 19 (9) 8 (11) 11 (8) 0.51
LVEF [%] 55 (40–60) 45 (37–55) 55 (50–60) < 0.001
LVEF ≤ 35% 35 (17) 18 (25) 17 (13) 0.03
Impaired renal function with 
eGFR < 60 mL/min
45 (22) 20 (27) 25 (19) 0.16
Dialysis 8 (4) 3 (4) 5 (4) 0.89
Prior acute coronary syndrome 130 (63) 50 (68) 80 (60) 0.21
Prior PCI 152 (73) 54 (74) 98 (73) 0.90
Prior CABG 31 (15) 29 (40) 2 (1) < 0.001
Laboratory parameters:
White blood cell count [103/µL] 7.7 ± 2.1 7.8 ± 2.3 7.7 ± 2.0 0.86
Red blood cell count [106/µL] 4.5 (4.1–4.8) 4.5 (4.0–4.8) 4.5 (4.2–4.8) 0.32
Haemoglobin [g/dL] 13.6 ± 1.4 13.4 ± 1.4 13.7 ± 1.4 0.12
Platelet count [103/µL] 205 (176–249) 203 (174–232) 210 (180–251) 0.24
Creatinine [mg/dL] 0.9 (0.8–1.1) 0.95 (0.8–1.2) 0.9 (0.8–1.1) 0.06
Glucose [mg/dL] 109 (96–134) 118 (102–140) 106 (96–130) 0.02
eGFR [mL/min/1.73 m2] 80 (63–94) 77 (58–93) 82 (70–94) 0.10
Risk scores:
Logistic EuroSCORE II 2.4 (1.4–4.9) 4.1 (2.4–7.1) 1.8 (1.2–3.5) < 0.001
Syntax Score 17 (11–24) 23 (16–32) 16 (9–22) < 0.001
Residual Syntax Score 8 (0–14) 12 (6–19) 6 (0–10) < 0.001
Syntax Revascularisation Index [%] 59 (42–100) 47 (33–62) 71 (47–100) < 0.001
Syntax Score II — PCI 5 (2) 1 (1) 4 (3) 0.47
Syntax Score II — CABG 45 (22) 24 (33) 21 (16) < 0.01
Syntax Score II — both 157 (76) 48 (66) 109 (81) 0.01
Medication at discharge:
ASA 201 (98) 70 (97) 131 (99) 0.53
P2Y12 inhibitor 203 (99) 70 (97) 133 (100) 0.06
b-blocker 195 (95) 70 (97) 125 (94) 0.30
ACEI/ARB 194 (94) 72 (99) 126 (95) 0.12
Statin 199 (96) 69 (94) 130 (97) 0.37
Diuretic 93 (45) 41 (57) 52 (39) 0.01
Nitrates 16 (8) 6 (8) 10 (8) 0.84
Oral anticoagulation 24 (12) 10 (14) 14 (11) 0.47
Proton pump inhibitor 100 (49) 36 (50) 64 (48) 0.84 
Data are presented as numbers (percentages) for categorical variables, mean ± standard deviation for continuous variables with normal distri-
bution, and median with interquartile range for continuous variables with skewed distribution. ACEI — angiotensin converting enzyme inhibitor; 
ARB — angiotensin receptor blocker; ASA — acetylsalicylic acid; CABG — coronary artery bypass grafting; COPD — chronic obstructive pulmonary 
disease; eGFR — estimated glomerular filtration rate; LVEF — left ventricular ejection fraction; PCI — percutaneous coronary intervention;  
RA — rotational atherectomy; TIA — transient ischaemic attack
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patients were disqualified from CABG. The main reasons were 
high-risk of surgery because of multiple comorbidities and 
challenging anatomy, including poor periphery of coronary 
arteries, which are acknowledged as contraindications [3–5]. 
Such patients can undergo further conservative treatment 
alone, which in the case of extensive symptomatic ischaemia 
has a poor prognosis [6–8]. The use of RA, even though it 
is a demanding technique for experienced operators, gives 
Table 2. Procedure characteristics
Patients All patients (n = 207) RA-only (n = 73) Remaining (n = 134) p
Acute coronary syndrome 165 (80) 23 (31) 19 (14) < 0.01
Radial access 125 (60) 38 (52) 87 (65) 0.07
Temporary pacing 19 (9) 13 (18) 26 (19) 0.78
MCS use 4 (2) 3 (4) 1 (1) 0.09
Reason for RA:
Uncrossable lesion 48 (23) 17 (23) 31 (23) 0.98
Undilatable lesion 105 (51) 39 (52) 67 (50) 0.78
Direct/Unclear PCI failure 54 (26) 18 (25) 36 (27) 0.60
Target vessel:
RCA 70 (34) 20 (27) 50 (37) 0.15
LM 11 (5) 6 (8) 5 (4) 0.17
LAD 92 (44) 32 (44) 60 (45) 0.90
Cx 29 (14) 15 (21) 14 (10) 0.05
Lesion characteristics:
Lesion type B2/C 186 (90) 66 (90) 120 (90) 0.84
Aorto-ostial lesion 27 (13) 13 (18) 14 (10) 0.13
Bifurcation lesion 81 (39) 29 (40) 52 (39) 0.90
Chronic total occlusion 23 (11) 9 (12) 14 (10) 0.68
Severe calcifications 186 (90) 69 (95) 117 (87) 0.10
Diameter stenosis [%] 95 (90–99) 95 (90–99) 90 (90–99) 0.24
Lesion length [mm] 24 (15–35) 26 (16–36) 23 (14–35) 0.20
Minimum lumen diameter [mm] 0.175 (0–0.525) 0.15 (0–0.52) 0.23 (0.03–0.54) 0.19
Reference diameter [mm] 3.1 (2.75–3.6) 3.0 (2.5–3.5) 3.1 (2.75–3.6) 0.43
Procedural data:
Predilatation 187 (92) 64 (89) 123 (93) 0.29
Postdilatation 108 (53) 38 (54) 70 (53) 0.95
More than one burr 41 (20) 11 (15) 30 (22) 0.20
Burr to artery ratio 0.43 (0.42–0.5) 0.43 (0.42–0.5) 0.43 (0.42–0.5) 0.58
Maximum burr diameter 1.5 ± 0.2 1.4 ± 0.2 1.5 ± 0.2 0.12
Number of stents 1.4 ± 0.9 1.4 ± 0.9 1.5 ± 0.8 0.43
DES implantations 184 (95) 63 (96) 121 (95) 0.78
Total contrast volume [mL] 250 (200–300) 250 (200–350) 250 (200–300) 0.15
Fluoroscopy time [min] 20 (15–29) 23 (16–30) 20 (14–28) 0.08
Procedure time [min] 85 (55–150) 90 (60–145) 85 (55–150) 0.45
Radiation exposure [µGy] 2623 (1686–4171) 2748 (1686–4429) 2483 (1717–4088) 0.42
Discharge after RA [days] 2 (1–4) 2 (2–5) 2 (1–3) 0.21
Procedural success 184 (89) 62 (85) 122 (91) 0.18
Data are presented as numbers and percentages for categorical variables, mean ± standard deviation for continuous variables with normal distri-
bution and median with interquartile range for continuous variables with skewed distribution. Cx — circumflex artery; DES — drug-eluting stent; 
LAD — left anterior descending; LM — left main; MCS — mechanical circulatory support; PCI — percutaneous coronary intervention;  
RA — rotational atherectomy; RCA — right coronary artery
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Table 3. In-hospital and one-year follow-up adverse events








Slow/no-flow 3 (1) 3 (4) 0 (0) 0.02
Side branch occlusion 5 (2) 3 (4) 2 (1) 0.24
Dissection 8 (4) 3 (4) 5 (4) 0.89
Perforation 3 (1) 0 (0) 3 (2) 0.20
Emergency CABG 0 (0) 0 (0) 0 (0) NS
Permanent pacing 0 (0) 0 (0) 0 (0) NS
In-hospital outcomes:
Death 2 (1) 1 (1) 1 (1) 0.66
Periprocedural MI 28 (14) 9 (12) 19 (14) 0.71
Stroke/TIA 1 (0.5) 0 (0) 1 (1) 0.46
Target vessel revascularisation 1 (0.5) 0 (0) 1 (1) 0.46
Contrast-induced nephropathy 6 (3) 3 (4) 3 (2) 0.44
Access site bleedings 14 (7) 8 (11) 6 (4) 0.08
Clinical outcomes at one-year follow-up:
Death 20 (10) 8 (11) 12 (9) 0.64
Follow-up MI 20 (10) 8 (11) 12 (9) 0.64
Stroke 2 (1) 0 (0) 2 (1) 0.29
MACE 38 (18) 14 (19) 24 (18) 0.82
 Data are presented as numbers (percentages). CABG — coronary artery bypass grafting; MACE — major adverse cardiac events; MI — myocardial 
infarction; NS — non-significant; RA — rotational atherectomy; TIA — transient ischaemic attack
Figure 1. Outcomes in patients after rotational atherectomy; 
MACE — major adverse cardiac events; MI — myocardial 
infarction; RA — rotational atherectomy
the patients the opportunity of successful revascularisation. 
Potential optimal evidence of RA efficacy in such a high-risk 
subgroup might be verified in a trial. However, randomising 
patients to PCI with RA and to optimal medical treatment 
alone seems difficult to perform, also from an ethical point 
of view, so all remaining patients who underwent RA were 
classified as a control group.
A large majority of the study group comprised higher-risk 
patients, with more frequent low LVEF < 35% (25% vs. 13%, 
p = 0.03), more often after CABG (40% vs. 1%, p < 0.001), 
and more often with acute coronary syndrome on admis-
sion (31% vs. 14%, p < 0.01), as compared to the control 
group. The presence of heart failure with decreased LVEF 
is a well-documented independent predictor of mortality, 
following not only conventional PCI procedure, but also PCI 
with accompanying RA [16, 17]. Patients with decreased LVEF 
undergoing complex PCI along with RA could be referred for 
more specialised treatment, such as the use of mechanical 
circulatory support (4% of our RA-only patients). The clinical 
status of the RA-only group was reflected by higher Euro-
SCORE II (4.1 vs. 1.8, p < 0.001) and the coronary status 
by higher SS (23 vs. 16, p < 0.001). In another trial patients 
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deemed by the Heart Team as inoperable also constituted 
a high-risk population, reaching 7.7 ± 9.0 in logistic Euro-
SCORE and 31.6 ± 12.3 in SS, and in another RA registry 
high EuroSCORE II had a significant association with MACE 
in long-term observation [9, 18].
Additionally, the level of incomplete revascularisation 
with the use of residual SS and SRI was assessed. The impor-
tance of incomplete revascularisation after PCI and its influ-
ence on prognosis have been raised in recent trials, indicating 
that high residual SS was associated with worse prognosis [19, 
20]. The SRI was introduced to assess reasonable incomplete 
revascularisation as well [21]. Both the abovementioned scales 
indicated the higher level of incomplete revascularisation in 
the study group compared to the control group. Fewer lesions 
Table 4. Predictors of outcome in Cox regression models
Univariate model Multivariate model
HR 95% CI p HR 95% CI p
Predictors of all-cause death:
LVEF ≤ 35% 5.64 2.34–13.55 < 0.001 4.85 1.72–13.67 < 0.01
Uncrossable lesion 3.64 1.51–8.74 < 0.01 4.33 1.71–10.94 < 0.01
Syntax Score 1.04 1.00–1.08 0.03 0.99 0.94–1.04 0.66
eGFR < 60 mL/min 2.58 1.05–6.31 0.04 1.36 0.47–3.93 0.57
EuroSCORE II 1.09 1.03–1.15 < 0.01 1.07 0.98–1.17 0.16
Predictors of major adverse cardiac events:
LVEF ≤ 35% 3.25 1.76–6.02 < 0.001 2.85 1.38–5.86 < 0.01
Uncrossable lesion 2.01 1.11–3.81 0.02 2.15 1.15–4.03 0.02
Syntax Score 1.03 1.01–1.06 0.01 0.99 0.97–1.03 0.81
Age 1.04 1.01–1.08 0.01 1.03 0.99–1.07 0.09
Diabetes mellitus 1.93 1.06–3.49 0.03 1.82 0.99–3.35 0.06
EuroSCORE II 1.07 1.03–1.12 < 0.01 1.03 0.98–1.10 0.26
CI — confidence interval; eGFR — estimated glomerular filtration rate; HR — hazard ratio; LVEF — left ventricular ejection fraction
Figure 2. Kaplan-Meier survival curves, log-rank p = 0.63;  
RA — rotational atherectomy
Figure 3. Kaplan-Meier major adverse cardiac event-free survival 
curves, log-rank p = 0.17; RA — rotational atherectomy
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were stented, presumably because mainly culprit lesions were 
treated whereas other lesions remained untouched, resulting 
in residual SS of 12 (vs. 6, p < 0.001) and SRI of 47% (vs. 71%, 
p < 0.001). Interestingly, according to SS II, which adds a few 
clinical parameters to the initial SS, one-third of our patients 
from the RA-only group might have better prognosis after 
potential CABG than after PCI. It highlights the impact of 
other comorbidities and overall status of the patient on Heart 
Team’s judgement regardless of different scores.
Thus, our clinical and coronary high-risk subpopulation 
had an unfavourable prognosis. Despite significant differences 
in characteristics between the high-risk and control groups, 
patients who underwent RA as the last resort for revascu-
larisation had similar rates of procedural success as well as 
in-hospital and one-year outcomes, including mortality, along 
with cardiovascular morbidity. RA-only criteria in regression 
analysis were also not associated with worse prognosis, and 
even partial revascularisation seemed reasonable in this se-
lected subgroup. The rate of periprocedural complications was 
relatively low and the only unfavourable parameter was more 
frequent no/slow-flow phenomenon (4% vs. 0%, respectively, 
p = 0.02) in the RA-only group, which was probably associ-
ated with the presence of complex atherosclerotic coronary 
lesions and did not have subsequent impact on in-hospital 
and one-year outcomes. Longer-term follow-up is warranted.
The results of the study may have practical implications 
and permit a more aggressive approach in selected high-risk 
patients, in whom conventional procedures are contraindi-
cated and conservative treatment is insufficient. Additional 
consultation in a centre specialising in treatment of patients 
recognised as CHIP should be considered not only by physi-
cians from low-volume centres, where complex procedures 
like rotational atherectomy are not performed, but also by 
members of the Heart Team.
The study was a nonrandomised observational registry 
from a single high-volume centre. The sample size was rela-
tively small, and the analyses should be considered as explora-
tive. Only all-cause mortality was reported during follow-up 
without differentiating the group of cardiac death patients.
To conclude, in clinical and coronary high-risk patients, 
no significant difference between in-hospital and one-year 
outcomes was found, in comparison to the remaining low-
er-risk patients undergoing RA. Complex PCI including RA in 
patients without other revascularisation options seems to be 
a safe and effective procedure with acceptable prognosis and 
should be taken into consideration.
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WHAT IS NEW?
Some of the patients with severe coronary artery disease constitute a high-risk population and the procedure of rotational 
atherectomy is their last resort for successful revascularisation. The study revealed that procedural success and one-year 
outcomes in such high-risk groups are similar to those in lower-risk routine rotablation groups in a high-volume centre. The 
results of the study may have practical implications and permit a more aggressive approach in selected high-risk patients, in 
whom conventional procedures are contraindicated and conservative treatment is insufficient. Additional consultation in 
a centre treating high-risk patients should be considered not only by specialists from low-volume centres, where complex 
procedures like rotational atherectomy are not performed, but also by members of the Heart Team.
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